Detalhe da pesquisa
1.
Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial.
Blood
; 143(1): 57-63, 2024 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37824808
2.
DNA polymerase θ protects leukemia cells from metabolically induced DNA damage.
Blood
; 141(19): 2372-2389, 2023 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36580665
3.
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.
Blood
; 140(12): 1345-1377, 2022 09 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35797463
4.
Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy.
Blood
; 140(25): 2663-2671, 2022 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35930750
5.
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
Nature
; 559(7712): 125-129, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29950729
6.
Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysis.
Cancer
; 129(16): 2479-2490, 2023 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37185873
7.
Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia.
Br J Haematol
; 200(2): 170-174, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36263593
8.
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
Blood
; 138(26): 2810-2827, 2021 12 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407545
9.
Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy.
Blood
; 137(2): 216-231, 2021 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33024998
10.
Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia.
Blood
; 137(10): 1377-1391, 2021 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32871587
11.
Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL.
Blood
; 138(11): 948-958, 2021 09 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33895809
12.
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Blood
; 137(13): 1792-1803, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33024987
13.
Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia.
Am J Hematol
; 98(12): 1869-1876, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37688521
14.
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.
Am J Hematol
; 98(1): 79-89, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36251406
15.
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
N Engl J Med
; 381(24): 2315-2326, 2019 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31826340
16.
How I treat relapsed or refractory AML.
Blood
; 136(9): 1023-1032, 2020 08 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32518943
17.
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Blood
; 135(7): 463-471, 2020 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31841594
18.
Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia.
Blood
; 135(5): 371-380, 2020 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31826241
19.
Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Ann Hematol
; 101(3): 557-569, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34981142
20.
Advances in the Treatment of Hairy Cell Leukemia Variant.
Curr Treat Options Oncol
; 23(1): 99-116, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35178674